DM Intelligence Ltd. participated the 5th Annual BFC HealthCare Business Development & Investment Conference
May 16, 2019
When DeepMind’s AlphaGo program defeated its human competitor at the ancient board game Go, it made a big splash in the AI scene. The field of AI has been actively growing since 2015. But 2017 became year of Cambrian explosion of AI in autonomous vehicles, facial recognition and search engines etc. As a particularly unique technology from the perspective of business models and value creation, it simulates (and often exceeds) human performance.
When it comes to healthcare, the cost of drug discovery and subsequent development is a massive challenge in the pharmaceutical industry. It takes 96.8 months to bring a new drug to market from drug discovery through clinical trials to approval, according to the data from Tufts Center for the Study of Drug Development. However, an analysis by Deloitte shows that cost of approved drugs from 12 big pharma increased by 33%, about 1.6 billion dollars per year. In summary, drug discovery is characterized by low speed, high cost, low efficiency and accuracy.
With the rise of AI, the breakthroughs in AI for drug discovery will change the R&D process of Bio Pharma, and it will make a tremendous impact on whole biopharma industry.
1. Target identification
2. Compound synthesis
3. Drug discovery
4. PK/PD prediction
5. Drug development
Naturally, there has been an increase in the number of companies focusing on implementing AI in drug R&D sector, while attracting more investments.
The field of AI in pharmaceutical has been growing rapidly. The pharmaceutical AI market in China has increased from less than 10 billion in 2016 to nearly 20 billion in 2018 at a CAGR of over 40%, expected to reach 40 billion by 2020. The healthcare sector is undergoing rapid transformation due to AI.
DM Intelligence Ltd. uses proprietary AI technology to screen small molecule drugs. Artificial Intelligence Drug Discovery Platform has been deployed to help find new candidates, supported by proprietary algorithm and big data sets.
The 2019 5th Annual BFC HealthCare Business Development & Investment Conference was held on May 15th-17th in Shanghai JW Marriott Hotel. DM Intelligence Ltd. participated in road show and introduced Artificial Intelligence Drug Discovery Platform. Investors and company representatives had close communications after road shows, which met BFC’s intention to provide a platform to facilitate the collaborations between enterprises and investors.
The immature but developing artificial intelligence technology is transforming pharmaceutical industry and significantly influence the capitalization of pharma company.